Super Saiyan of Pharmacy YouTube: https://nitter.cf/t.co/z0CxaNvkkF
Chicago, IL
Joined February 2022
- Tweets2.2K
- Following446
- Followers733
- Likes7.6K
Pinned Tweet
What happens when the mortality benefit of a miracle sepsis drug suddenly… disappears? Join me for a quick discussion on Xigris and the origins of Surviving Sepsis!
Xigris, Eli Lilly, and the Surviving Sepsis Marketing Machine youtube.com/shorts/DK98XJbV4… via @YouTube
We’ve covered the three easy to treat UTIs, and now on to the really f*!@in’ complicated one! Can we really afford to mess around with complicated CRE UTIs?
#pharmacist #pharmacy #IDPharmacist #IDSA #CRE
youtube.com/shorts/jasHmE9XC…
Mixing metronidazole and alcohol has been a big no-no for years – but is this based on any real evidence? Let’s take a deep dive into the shallow pool of data!
#Pharmacist #Pharmacy #Mythbusting
youtube.com/shorts/6yzNKhOsB…
Let’s take a look at the Surviving Sepsis Guidelines and see just how often blood cultures hit, and what we can do to get the most out of them!
#Pharmacist #Pharmacy #Sepsis #ICUPharmacist #IDPharmacist
youtube.com/shorts/3O1zS-MZl…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
🆕🔥🟢FAST-ROCKET
A multicenter, retrospective study(N:639)
The first study to compare clinical outcomes between patients who received cefepime & meropenem in a subset of patients with AmpC-ECK E bacteremia expressing baseline ceftriaxone resistance(MIC > 1 µg/mL)
🔺Among patients infected by ceftriaxone-resistant AmpC-E, carbapenems were used as definitive treatment in 30% (65/214), while cefepime was used for definitive treatment in 41% (88/214)
🔺After propensity score weighting, no statistically significant difference in 30-day mortality (HR, 1.08; 95% CI, 0.49–2.39; P= 0.848) was observed between patients infected by ceftriaxone-resistant AmpC-ECK E who received definitive treatment with meropenem or cefepime #IDXposts
sciencedirect.com/science/ar…
Treating CRE is no joke, so why is IDSA joking around? A lot of these suggestions are a roll of the dice – probably not the way I would go if I was writing a gram negative guidance document!
#pharmacist #pharmacy #IDPharmacist #IDSA #CRE
youtube.com/shorts/QXm0wco8D…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
Fosfo for pyelo letter/meta-analysis is published. doi.org/10.1093/cid/ciag552
Surely, it can't be CRE... but sometimes, it is! Let's talk about resistance mechanisms and some background for CRE!
#pharmacist #pharmacy #IDPharmacist #IDSA #CRE
youtube.com/shorts/HpXvh00vG…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
However...... May I share this preprint?
medrxiv.org/content/10.64898…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
Join us at #AMCP2026 in San Diego!
I'll be presenting alongside Dr. Alex Sandhu and Dr. Bridget O'Connell on secondary CVD risk, and sharing recent updates on lipid management.
@amcporg #AMCPNexus
amcpnexus.org/
Surviving Sepsis 2026 was a bit dense - so let's break it down! First up, let's talk about scoring systems!
#Pharmacist #Pharmacy #IDSA
youtube.com/shorts/-Tjmnz-WU…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
Join @PharmDFarmD and I as we discuss new-onset AFib in the ICU! Should we anticoagulate or hold off? Let’s look at the data!
A short acting drug that suddenly develops a long half-life? That’s fentanyl! Let’s talk about fentanyl infusions!
#Pharmacist #Pharmacy #Fentanyl #ICUPharmacist #SAT
youtube.com/shorts/3gB1EJ_bf…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
Updated Shorter Is Better tables! @absteward found a 2 wk vs. 12 wk 2-stage PJI RCT. Also @rachelpbaden identified a duplication in the CAP trials, so there are now 14 RCTs for CAP, not 15. Updated refs at
bradspellberg.com/shorter-is…
When they look right… You go left! Why bother with beta lactamase inhibitors and new drugs when we can cover AmpC with non-beta lactams! Let’s take a look at our options!
#pharmacist #pharmacy #IDPharmacist #IDSA #AmpC
youtube.com/shorts/1SDvNIRzS…
Happy pharmacy week!
Come join me and several other pharmacists as we discuss some of our favorite things about being pharmacists!
instagram.com/reel/DeqTyvCOt…
New Beta Lactams and Beta Lactamase Inhibitor Combos for AmpC-E? Hold your horses there, buddy! While these drugs may work, we probably have some better options!
#pharmacist #pharmacy #IDPharmacist #IDSA #AmpC
youtube.com/shorts/pvtoNSsnh…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
There is no standardized treatment catastrophic brain injury (CBI), a fatal injury. Giving dopamine, DDAVP, vasopressin, levothyroxine, or steroids alone: ↑ odds of organ donation after CBI. DDAVP and steroids together have the highest odds of successful donation.
@KristenNordham @STaghaviMD
ovid.com/jnls/jtrauma/abstra…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
🔥It's published 🔥
The first ever RCT combination therapy for Stenotrophomonas maltophelia infections
Efficacy of combination therapy with minocycline for treating Stenotrophomonas maltophilia infections
🔺Adjunctive minocycline did not significantly reduce 28-day-mortality (n = 24/55[43.6%] vs n = 22/57[38.6%], P = 0.590) #IDXposts @drgabx
academic.oup.com/jacamr/arti…
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
Calling MedTwitter! If you have had it with clinical guidelines recommending things not based on evidence, PLEASE SIGN THIS PETITION CALLING ON SPECIALTY SOCIETIES TO REFORM THE GUIDELINES PROCESS!
gopetition.com/petitions/ref…
@ABsteward @DrToddLee @PulmCrit @nickmmark @medrants
The 1st of 2 new articles in CID critical of clinical guideline process is out. See
academic.oup.com/cid/article…
It is long past time clinical guidelines incorporate the humility of uncertainty & stop creating standards of care absent of reproducible prospective studies.
@ABsteward
Andrew Desio, PharmD BCPS BCCP BCCCP BCIDP retweeted
Fresh blog: Hot take on the VASSPR trial 🔥
🗜️Numerous correlational and target-trial-emulation studies published in the past five years suggested that early vasopressin initiation could cause huge mortality benefits.
🗜️ The VASSPR trial, a new multicenter RCT, shows that early initiation of vasopressin doesn't affect mortality or renal failure.
🗜️This is a great illustration of why we need RCTs. Sometimes a dozen retrospective & target-trial emulation studies are all consistently wrong.
🗜️Vasopressin can impair digital perfusion, which may be VERY problematic if you're using capillary refill time as a resuscitative target. (#1/2)
